ArticleScientific reports2026
Stage-dependent prognostic impact of age in colorectal cancer: A population-based SEER analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognostic association between age and colorectal cancer (CRC) survival may vary by stage. We analyzed adults with microscopically confirmed CRC diagnosed during 2004-2022 in the Surveillance, Epidemiology, and End Results database after excluding appendiceal primaries, death certificate-only/autopsy-only cases, and non-microscopically confirmed cases. Multivariable Cox models assessed age continuously, and age-by-stage interaction models compared patients aged 18-49 versus ≥ 50 years among those with known stage. The primary survival cohort included 454,216 patients; multivariable Cox models were fitted in 452,739 patients. Increasing age was associated with worse cancer-specific survival (CSS; HR 1.0279/year, 95% CI 1.0275-1.0284) and overall survival (OS; HR 1.0443/year, 95% CI 1.0440-1.0447). Age-by-stage interaction was significant for both endpoints. For CSS, the association of age ≥ 50 years was strongest in localized disease (HR 2.17, 95% CI 2.04-2.31) and attenuated in regional (HR 1.58, 95% CI 1.54-1.63) and distant disease (HR 1.41, 95% CI 1.38-1.44), with a similar pattern for OS. Older age was associated with worse CRC survival, but the magnitude of this association was stage-dependent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.